Search clinical trials for: treatment-naive

Total 15 results

Beijing Friendship Hospital
Xiangya Hospital of Central South University; Beijing YouAn Hospital; The Affiliated... and other collaborators

Not yet recruiting

Re-compensation and Its Clinical Characteristics in HBV Decompensated Cirrhosis

Decompensated Cirrhosis | Hepatitis B

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Sintilimab in Combination With R-CHOP in Patients With Treatment-naive EBV-positive DLBCL, NOS

EBV-Positive DLBCL, Nos

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLL (BDHCLL001)

Chronic Lymphocytic Leukemia

China
Novartis Pharmaceuticals

Completed

Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health)

Age-related Macular Degeneration (AMD)

United States
Novartis Pharmaceuticals

Completed

Evaluation of Number of Patient Eyes That Remained on or Switched to Anti-VEGF Treatment After Initiation of Broluciumab

Age-related Macular Degeneration (AMD)

United States
Tehran University of Medical Sciences

Completed

Cyclosporine-A Versus Prednisolone for Induction of Remission in Auto-immune Hepatitis

Autoimmune Hepatitis

Iran, Islamic Republic of
GlaxoSmithKline

Completed

Pharmacokinetics And Pharmacodynamics Of Lapatinib In Two Dosing Regimens In Treatment-naive Patients With Breast Cancer

Neoplasms, Breast

United States, Israel
Merck Sharp & Dohme LLC

Completed

Study of Hepatitis C Virus (HCV) Nonstructural Protein 5a (NS5A) Inhibitor IDX719 in Healthy and HCV-Infected Participants (MK-1894-001)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks (MK-2355-005)

Hepatitis C, Chronic
Timothy Morgan, MD
Vertex Pharmaceuticals Incorporated

Withdrawn

Vitamin D + Telaprevir + Peginterferon + Ribavirin for of Hepatitis C Genotype 1

Hepatitis C

United States
Janssen-Cilag International NV

Completed

A Clinical Trial Comparing the Tolerability of Etravirine to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Treatment-naive HIV-1 Infected Patients (SENSE)

Acquired Immunodeficiency Syndrome | HIV Infection | HIV

France, United Kingdom, Germany, Spain, Switzerland, Israel, Russian Federation, Austria, Hungary, Romania, Denmark
LG Life Sciences

Completed

Safety and Efficacy Study of LB80380 in the Treatment-naive Patients of Chronic Hepatitis B

Chronic Hepatitis B

Korea, Republic of, China
LG Life Sciences

Unknown

Long-term Safety and Efficacy Study of LB80380 in the Treatment-naive Patients of Chronic Hepatitis B (LB80380)

Chronic Hepatitis B

China, Korea, Republic of
Merck Sharp & Dohme LLC
Novartis Pharmaceuticals

Completed

Study to Evaluate Drug-drug Interaction Between Valopicitabine and Ribavirin

Chronic Hepatitis C

United States
University Hospital, Saarland
Hoffmann-La Roche

Unknown

Peginterferon Alfa-2a, Ribavirin, Amantadine/Placebo in Hepatitis C Virus (HCV)-Genotype-1-Infection (PRAMA)

Hepatitis C, Chronic

3

Subscribe